Results 151 to 160 of about 330,598 (225)

Blood tumor load: combining biomarkers to increase the proportion of informative patients. [PDF]

ESMO Open
Dathathri E, Nanou A, Bidard FC, Renault S, Pierga JY, de Bono J, Terstappen L, Coumans FAW.   +7 more
europepmc   +1 more source

Oxytocin Enhances Demethylation Through TET Enzyme Expression in Neurons of Aged Mice: Oxytocin as a Potential Antiaging Peptide

Aging Cell, EarlyView.
DNA methylation, mitochondrial dysfunction, inflammation, and senescence interact to form a vicious cycle. Here we report that oxytocin interrupts this vicious cycle by increasing TET2 expression, inducing DNA demethylation in aged neurons and raising plasma oxytocin levels, decreasing systemic inflammation.
Yuko Maejima, Shoko Yokota, Megumi Yamachi, Shizu Hidema, Tomoyuki Ono, Shu Taira, Katsuhiko Nishimori, Heidi de Wet, Kenju Shimomura   +8 more
wiley   +1 more source

Circulating Biomarkers of Thyroid Cancer: An Appraisal. [PDF]

J Clin Med
Codrich M, Biasotto A, D'Aurizio F.
europepmc   +1 more source

Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2‐Year Post‐Marketing Surveillance

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This post hoc analysis of a post‐marketing surveillance evaluated the prognosis of patients with invasive lobular carcinoma (ILC) or invasive ductal carcinoma (IDC) treated with eribulin. Overall survival (OS) from the first‐line chemotherapy was shorter for ILC than IDC cases, but OS from the first date of eribulin administration were similar between ...
Yuko Tanabe, Kenichi Inoue, Masato Takahashi, Hirofumi Mukai, Takashi Yamanaka, Chiyomi Egawa, Yohei Uchida, Yoichi Higashibeppu, Yukinori Sakata, Michiko Sugawara, Junji Tsurutani   +10 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

The Flow Cytometric Evaluation of B- and T-Lymphoblastic Leukemia/Lymphoma. [PDF]

Cancers (Basel)
Dorfman DM.
europepmc   +1 more source

IgG4‐Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets

Allergy, EarlyView.
ABSTRACT IgG4, the least abundant IgG subclass in humans, is increasingly recognised for its involvement in allergic and autoimmune pathologies. Its unique properties, such as the tendency to form half‐molecules (one heavy chain and one light chain) and its generally non‐inflammatory nature, distinguish it from other IgG subclasses.
Louisa Tedesco, Syed B. Ali, Baran Erman, Safa Baris, Harshita Pant, Pravin Hissaria, Yelda Bilginer, Damon J. Tumes, Gökhan Cildir   +8 more
wiley   +1 more source

Tumor Microenvironment in Melanoma Brain Metastasis: A New Potential Target? [PDF]

Int J Mol Sci
Caruso G, Garcia Moreira CG, Iaboni E, Tripodo M, Ferrarotto R, Abbritti RV, Conte L, Caffo M.   +7 more
europepmc   +1 more source